{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:27:04Z","timestamp":1793262424810,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e35990","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T10:13:18Z","timestamp":1723111998000},"page":"e35990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Physician preferences for treatment of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease (ASCVD)\u2013A discrete choice experiment"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6240-8867","authenticated-orcid":false,"given":"Marlon","family":"Graf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit V.","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suepattra G.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukyung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"N'dri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Cristino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batul","family":"Electricwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e35990_bib1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jacl.2016.06.011","article-title":"Prevalence of the American College of Cardiology\/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011\u20132012","volume":"10","author":"Wong","year":"2016","journal-title":"Journal of clinical lipidology"},{"key":"10.1016\/j.heliyon.2024.e35990_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"American Journal of Preventive Cardiology"},{"key":"10.1016\/j.heliyon.2024.e35990_bib3","series-title":"Cholesterol Management Guide for Healthcare Practitioners","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e35990_bib4","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e35990_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017793","article-title":"Financial toxicity in atherosclerotic cardiovascular disease in the United States: current state and future directions","volume":"9","author":"Khera","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.heliyon.2024.e35990_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.2849","article-title":"Economic burden of atherosclerotic cardiovascular disease: costs related to healthcare and loss of productivity; a matched case-control study in more than 450,000 Swedish individuals","volume":"43","author":"Carlsson","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2024.e35990_bib7","article-title":"Abstract 18529: trends in direct healthcare expenditures among US adults with atherosclerotic cardiovascular disease: analysis of the medical expenditure panel survey from 2002 to 2013","volume":"134","author":"Valero-Elizondo","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e35990_bib8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e35990_bib9","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e35990_bib10","doi-asserted-by":"crossref","DOI":"10.4137\/LPI.S37450","article-title":"Current and emerging uses of statins in clinical therapeutics: a review","volume":"9","author":"Davies","year":"2016","journal-title":"Lipid Insights"},{"key":"10.1016\/j.heliyon.2024.e35990_bib11","first-page":"191","article-title":"Safety and tolerability of PCSK9 inhibitors: current insights","volume":"12","author":"Kosmas","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e35990_bib12","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.041974","article-title":"Cost-related medication nonadherence in adults with atherosclerotic cardiovascular disease in the United States, 2013 to 2017","volume":"140","author":"Khera","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e35990_bib13","series-title":"Clinical Consequences of Poor Adherence to Lipid-Lowering Therapy in Patients with Cardiovascular Disease: Can We Do Better?","author":"Klimis","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e35990_bib14","first-page":"e1082","article-title":"Guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e35990_bib15","series-title":"Evaluation of Perceptions, Knowledge and Compliance with Guidelines in Real-Life Practice: a Survey on the Under-treatment of Hypercholesterolemia","author":"Do\u011fan","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e35990_bib16","volume":"vol. 51","author":"Karakayal\u0131","year":"2023"},{"key":"10.1016\/j.heliyon.2024.e35990_bib17","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacl.2023.09.013","article-title":"Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: real-life evidence from the EPHESUS registry","volume":"17","author":"Kay\u0131kcioglu","year":"2023","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.heliyon.2024.e35990_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2021.04.034","article-title":"Perceptions and barriers on the use of proprotein subtilisin\/kexin type 9 inhibitors in heterozygous familial hypercholesterolemia (from a survey of primary care physicians and cardiologists)","volume":"152","author":"Wong","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.heliyon.2024.e35990_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force","volume":"16","author":"Johnson","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.heliyon.2024.e35990_bib20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.amjcard.2018.12.031","article-title":"Association of clinician knowledge and statin beliefs with statin therapy use and lipid levels (a survey of US practice in the PALM registry)","volume":"123","author":"Lowenstern","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.heliyon.2024.e35990_bib21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijmedinf.2014.04.007","article-title":"Physician and patient willingness to pay for electronic cardiovascular disease management","volume":"83","author":"Deal","year":"2014","journal-title":"Int. J. Med. Inf."},{"key":"10.1016\/j.heliyon.2024.e35990_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40273-014-0223-1","article-title":"Reduce mortality risk above all else: a discrete-choice experiment in acute coronary syndrome patients","volume":"33","author":"M\u00fchlbacher","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.heliyon.2024.e35990_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.socscimed.2018.06.011","article-title":"Comparing mortality risk reduction, life expectancy gains, and probability of achieving full life span, as alternatives for presenting CVD mortality risk reduction: a discrete choice study of framing risk and health behaviour change","volume":"211","author":"Grisol\u00eda","year":"2018","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.heliyon.2024.e35990_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/heartjnl-2018-314103","article-title":"Individual preferences on the balancing of good and harm of cardiovascular disease screening","volume":"105","author":"Hansen","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.heliyon.2024.e35990_bib25","series-title":"Stated Choice Methods: Analysis and Applications","author":"Louviere","year":"2000"},{"key":"10.1016\/j.heliyon.2024.e35990_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.heliyon.2024.e35990_bib27","series-title":"Physician Specialty Data Report","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e35990_bib28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamacardio.2019.3247","article-title":"Current demographic status of cardiologists in the United States","volume":"4","author":"Mehta","year":"2019","journal-title":"JAMA cardiology"},{"key":"10.1016\/j.heliyon.2024.e35990_bib29","series-title":"AAFP Member Demographics","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e35990_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.heliyon.2024.e35990_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ahj.2017.08.005","article-title":"Lipid management in contemporary community practice: results from the provider assessment of lipid management (PALM) registry","volume":"193","author":"Navar","year":"2017","journal-title":"Am. Heart J."},{"key":"10.1016\/j.heliyon.2024.e35990_bib32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wi de Cross-Section al Obser v at ion al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"European journal of preventive cardiology"},{"key":"10.1016\/j.heliyon.2024.e35990_bib33","article-title":"Nonadherence to lipid\u2010lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease","author":"Desai","year":"2022","journal-title":"Clin. Cardiol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402412021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402412021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:48:25Z","timestamp":1773182905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402412021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S240584402412021X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35990","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physician preferences for treatment of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease (ASCVD)\u2013A discrete choice experiment","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e35990"}}